Moderna-Merck melanoma vaccine cut recurrence and death risk 42% in trial
Moderna and Merck's personalized mRNA melanoma vaccine lowered the combined risk of recurrence or death by 42% against standard treatment in a late-stage trial, and six specialists called it meaningful.
Moderna and Merck's personalized mRNA vaccine for melanoma lowered the risk of the cancer returning or of death by 42%, compared with standard treatment, in a late-stage trial. NBC News and Ars Technica both report the figure.
The companies had already said the trial succeeded. Ars Technica reports the latest release gave the top-line results. The New York Times reports the companies put out detailed results, and says the vaccine cut the risk of melanoma recurrence.
CNBC reports that six melanoma specialists called the results clinically meaningful for patients who have had surgery. CNBC's headline says the doctors saw it as a major advancement, despite the reaction on Wall Street. The excerpt does not describe that reaction.
The vaccine is still experimental.
Reported by
- Ars TechnicaModerna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%Thu, Oct 22, 6:12 PM EDT
- The New York TimesCancer Vaccine Cuts the Risk of Melanoma Recurrence, Merck and Moderna ReportThu, Oct 22, 6:48 PM EDT
- CNBCDoctors call Moderna, Merck cancer vaccine data a major advancement — despite Wall Street reactionFri, Oct 23, 12:24 PM EDT
- NBC NewsPersonalized mRNA vaccine for melanoma cut risk of cancer’s return in late-stage trialFri, Oct 23, 2:42 PM EDT
This story was written by AI using only the reports listed above, and published without a person reviewing it first. It is rewritten as new reports arrive. Read the original reporting for full detail. Spot an error? Tell us.
Earlier versions (2)
- Fri, Oct 23, 12:30 PM EDT, 3 outlets: Melanoma specialists call Moderna-Merck vaccine results meaningful for surgery patients
- Thu, Oct 22, 8:20 PM EDT, 2 outlets: Moderna and Merck report mRNA melanoma vaccine cut recurrence and death by 42%